Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.48 |
| ▸ | APLNR | P35414 | 8/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22497182 | 1.00 | TAS2R14 (0.48) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL20757394 | 1.00 | TAS2R14 (0.48) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL22497274 | 0.89 | APLNR (0.44) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL22497306 | 0.89 | APLNR (0.44) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL22497273 | 0.89 | APLNR (0.44) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL30365840 | 0.89 | APLNR (0.46) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL29284977 | 0.89 | APLNR (0.46) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL23294081 | 0.88 | APLNR (0.45) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL20757826 | 0.88 | APLNR (0.45) | TAS2R14APLNRPTGESTAS2R8CXCR3 | |
| SCHEMBL23850777 | 0.87 | APLNR (0.47) | TAS2R14APLNRPTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4408843-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| WO-2023056264-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-04-06 | — | — | WO | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | TAS2R14 441/4885APLNR 2732/4885PTGES 1579/4885 |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, PYCARD | TAS2R14 1024/4885APLNR 2957/4885PTGES 1555/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | TAS2R14 991/4885APLNR 3254/4885PTGES 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.